A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
Status:
Active, not recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
This study will assess pexidartinib in adult participants with symptomatic TGCT that is
associated with severe morbidity or functional limitations and not amendable to improvement
with surgery.